HPV Vaccine Deal Gives GSK Royalties From Merck's Product

A cross-licensing deal between Merck and GlaxoSmithKline settles a dispute over several patents relating to separate Phase III human papilloma virus vaccines. Merck will make an upfront payment to GSK and pay royalties. MedImmune and Australia-based CSL may now receive payments from both companies.